Zacks: Analysts Anticipate MEDNAX Inc (NYSE:MD) to Announce $0.88 EPS

Equities research analysts expect MEDNAX Inc (NYSE:MD) to report earnings of $0.88 per share for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have provided estimates for MEDNAX’s earnings, with the highest EPS estimate coming in at $0.92 and the lowest estimate coming in at $0.83. MEDNAX posted earnings of $1.07 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 17.8%. The firm is expected to issue its next quarterly earnings results on Thursday, August 1st.

According to Zacks, analysts expect that MEDNAX will report full year earnings of $3.47 per share for the current fiscal year, with EPS estimates ranging from $3.28 to $3.61. For the next year, analysts forecast that the company will post earnings of $3.93 per share, with EPS estimates ranging from $3.39 to $4.66. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for MEDNAX.

MEDNAX (NYSE:MD) last announced its quarterly earnings results on Thursday, May 2nd. The company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.63 by ($0.05). MEDNAX had a positive return on equity of 9.82% and a negative net margin of 1.05%. The company had revenue of $851.20 million during the quarter, compared to the consensus estimate of $906.35 million. During the same quarter in the prior year, the firm earned $0.89 earnings per share. The business’s revenue was down .2% compared to the same quarter last year.

A number of research firms recently issued reports on MD. Citigroup set a $36.00 price objective on shares of MEDNAX and gave the stock a “buy” rating in a report on Friday, May 3rd. Zacks Investment Research downgraded shares of MEDNAX from a “hold” rating to a “sell” rating in a report on Monday, April 22nd. Finally, Jefferies Financial Group dropped their price objective on shares of MEDNAX from $37.00 to $31.00 and set a “hold” rating on the stock in a report on Thursday, April 11th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $40.55.

Shares of MD stock traded down $0.48 during trading hours on Friday, reaching $25.91. The company had a trading volume of 8,845 shares, compared to its average volume of 881,717. MEDNAX has a one year low of $24.30 and a one year high of $48.77. The firm has a market capitalization of $2.24 billion, a PE ratio of 7.38, a P/E/G ratio of 1.00 and a beta of 0.66. The company has a quick ratio of 2.55, a current ratio of 2.55 and a debt-to-equity ratio of 0.79.

A number of large investors have recently modified their holdings of MD. Vanguard Group Inc lifted its holdings in MEDNAX by 3.9% during the third quarter. Vanguard Group Inc now owns 8,282,555 shares of the company’s stock valued at $386,464,000 after purchasing an additional 314,415 shares in the last quarter. Xact Kapitalforvaltning AB increased its position in MEDNAX by 10.0% in the fourth quarter. Xact Kapitalforvaltning AB now owns 16,500 shares of the company’s stock worth $544,000 after purchasing an additional 1,500 shares during the last quarter. Rhumbline Advisers increased its position in MEDNAX by 39.5% in the fourth quarter. Rhumbline Advisers now owns 239,523 shares of the company’s stock worth $7,904,000 after purchasing an additional 67,867 shares during the last quarter. First Mercantile Trust Co. increased its position in MEDNAX by 13.8% during the fourth quarter. First Mercantile Trust Co. now owns 2,275 shares of the company’s stock valued at $76,000 after acquiring an additional 275 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System increased its position in MEDNAX by 1.8% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 134,507 shares of the company’s stock valued at $4,439,000 after acquiring an additional 2,411 shares during the last quarter. 91.19% of the stock is currently owned by institutional investors and hedge funds.

MEDNAX Company Profile

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.

Further Reading: How Do Mutual Funds Work?

Get a free copy of the Zacks research report on MEDNAX (MD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.